Publications by authors named "Ezekiel B Quittner-Strom"
Article Synopsis
- The FOXN3 gene variant rs8004664 is linked to elevated fasting blood glucose levels in non-diabetic individuals, without influencing insulin levels.
- Research shows that individuals with this genetic variant have heightened FOXN3 expression in liver cells, and manipulating FOXN3 levels affects fasting blood glucose in model organisms like zebrafish.
- Glucagon and FOXN3 interact to jointly regulate fasting glucose levels, with glucagon reducing FOXN3 expression and FOXN3 overexpression leading to an increase in glucagon-producing α cells.
The antidiabetic potential of glucagon receptor antagonism presents an opportunity for use in an insulin-centric clinical environment. To investigate the metabolic effects of glucagon receptor antagonism in type 2 diabetes, we treated Lepr and Lep mice with REMD 2.59, a human monoclonal antibody and competitive antagonist of the glucagon receptor.
View Article and Find Full Text PDFPeroxisome proliferator-activated receptor α (PPARα) is a nuclear hormone receptor that promotes fatty acid β-oxidation (FAO) and oxidative phosphorylation (OXPHOS). We and others have recently shown that PPARα and its target genes are downregulated, and FAO and OXPHOS are impaired in autosomal dominant polycystic kidney disease (ADPKD). However, whether PPARα and FAO/OXPHOS are causally linked to ADPKD progression is not entirely clear.
View Article and Find Full Text PDF